The current stock price of ALDR is 18.88 null. In the past month the price increased by 1.34%. In the past year, price increased by 43.36%.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington.
Alder Biopharmaceuticals Inc
11804 NORTH CREEK PARKWAY SOUTH
BOTHELL WA 98011
CEO: Robert W. Azelby
Phone: 425-205-2900
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington.
The current stock price of ALDR is 18.88 null. The price decreased by -0.21% in the last trading session.
ALDR does not pay a dividend.
ALDR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALDR.
Alder Biopharmaceuticals Inc (ALDR) has a market capitalization of 1.58B null. This makes ALDR a Small Cap stock.
ChartMill assigns a technical rating of 8 / 10 to ALDR. When comparing the yearly performance of all stocks, ALDR is one of the better performing stocks in the market, outperforming 98.26% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to ALDR. Both the profitability and financial health of ALDR have multiple concerns.
Over the last trailing twelve months ALDR reported a non-GAAP Earnings per Share(EPS) of -4.449999999999999. The EPS increased by 0.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.61% | ||
| ROE | N/A | ||
| Debt/Equity | 0.89 |